Australien - engelska - Department of Health (Therapeutic Goods Administration)

horseley dental supplies pty ltd - 41397 - orthodontic archwire - use to cause or guide tooth movement in dental orthodontic procedures.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

naol australia pty ltd - 41397 - orthodontic archwire - a dental wire used with orthodontic attachments, affixed to crowns of two or more teeth in order to cause or guide tooth movement

Irland - engelska - Ecolab

ecolab deutschland gmbh -

Storbritannien - engelska - Ecolab

ecolab deutschland gmbh -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 41397 - orthodontic archwire - intended for use in orthodontic treatment. a dental wire used with orthodontic attachments, affixed to the crowns of two or more teeth in order to cause or guide tooth movement.

USA - engelska - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - warfarin sodium tablets usp are indicated for: prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. pregnancy warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.5) and use in specifi

USA - engelska - NLM (National Library of Medicine)

northwind pharmaceuticals - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - codeine phosphate 30 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] have not provided adequate analgesia, or are not expected to provide adequate analgesia have not been tolerated, or are not expected to be tolerated please review the manufacturer's complete drug information available from the fda at www.fda.gov permanent link: https://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?setid=02386806-02d4-47e3-9c8b-7810146ee795 acetaminophen and codeine phosphate tablets are contraindicated in patients with: patients with significant respiratory depression [see warnings].

USA - engelska - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 20 mg - citalopram, is indicated for the treatment of depression. the efficacy of citalopram hydrobromide, in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied

USA - engelska - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - topiramate (unii: 0h73wjj391) (topiramate - unii:0h73wjj391) - topiramate 50 mg - 1.1 monotherapy epilepsy topiramate tablets usp are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials [see clinical studies (14.1)]. 1.2 adjunctive therapy epilepsy topiramate tablets usp are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with lennox-gastaut syndrome none. 8.1 pregnancy pregnancy category d. [see warnings and precautions (5.7)] topiramate can cause fetal harm when administered to a pregnant woman. data from pregnancy registries indicate that infants exposed to topiramate in utero have an increased risk for cleft lip and/or cleft palate (oral clefts). when multiple

USA - engelska - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole 20 mg - 1.1 duodenal ulcer (adults) omeprazole delayed-release capsules, usp are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. omeprazole delayed-release capsules, usp, in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. omeprazole delayed-release capsules, usp, in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [seeclinical studies (14.1) and dosage and administration (2)]. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance